Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308608833> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4308608833 abstract "Abstract Aim: we sought to estimate the association between hypoglycemic medications especially sodium-glucose co-transporter-2 inhibitors (SGLT2i) and osteomyelitis based on the FDA adverse event reporting system (FAERS). Methods: Publicly available FAERS data were analyzed using reporting odd ratio (ROR) method and Bayesian confidence propagation neural network (BCPNN) method. The developing trend of ROR were revealed by series of calculation based on accumulating dataset quarter by quarter. Results: Ketoacidosis, infections, peripheral ischemia, renal impairment, inflammation including osteomyelitis might more likely to occur among SGLT2i users, especially canagliflozin. Osteomyelitis and cellulitis are AEs unique to canagliflozin. Among 2,888 osteomyelitis-related reports referring to glucose lowering medications, 2,333 cases were associated with SGLT2i, mostly with canagliflozin counting 2,283 which generated an ROR value of 360.89 and a lower limit of information component (IC025) of 7.79. No BCPNN-positive signal could be generated for drugs other than insulin, canagliflozin or drug groups excluding canagliflozin. Reports referring to insulin could generate BCPNN-positive signals during the entire timespan from 2004 to 2021, while BCPNN-positive signal emerged since second quarter (Q2) of 2017, four years since the approval of SGLT2i in Q2 of 2013, for canagliflozin and drug groups containing canagliflozin. Conclusion: This data mining revealed that strong association between canagliflozin treatment and developing osteomyelitis which might be a precursor to lower extremity amputation. Further study with updated data is needed to better characterize the risk of osteomyelitis associated with SGLT2i." @default.
- W4308608833 created "2022-11-13" @default.
- W4308608833 creator A5050282209 @default.
- W4308608833 creator A5052441498 @default.
- W4308608833 creator A5056068917 @default.
- W4308608833 creator A5056437949 @default.
- W4308608833 creator A5061646378 @default.
- W4308608833 creator A5078976003 @default.
- W4308608833 creator A5081946864 @default.
- W4308608833 date "2022-11-09" @default.
- W4308608833 modified "2023-10-18" @default.
- W4308608833 title "Sodium-glucose co-transporter-2 inhibitors (SGLT2i) treatment and risk of osteomyelitis: a pharmacovigilance study of the FAERS database" @default.
- W4308608833 doi "https://doi.org/10.22541/au.166800072.20041282/v1" @default.
- W4308608833 hasPublicationYear "2022" @default.
- W4308608833 type Work @default.
- W4308608833 citedByCount "0" @default.
- W4308608833 crossrefType "posted-content" @default.
- W4308608833 hasAuthorship W4308608833A5050282209 @default.
- W4308608833 hasAuthorship W4308608833A5052441498 @default.
- W4308608833 hasAuthorship W4308608833A5056068917 @default.
- W4308608833 hasAuthorship W4308608833A5056437949 @default.
- W4308608833 hasAuthorship W4308608833A5061646378 @default.
- W4308608833 hasAuthorship W4308608833A5078976003 @default.
- W4308608833 hasAuthorship W4308608833A5081946864 @default.
- W4308608833 hasBestOaLocation W43086088331 @default.
- W4308608833 hasConcept C126322002 @default.
- W4308608833 hasConcept C134018914 @default.
- W4308608833 hasConcept C141071460 @default.
- W4308608833 hasConcept C197934379 @default.
- W4308608833 hasConcept C2775887513 @default.
- W4308608833 hasConcept C2777105317 @default.
- W4308608833 hasConcept C2777180221 @default.
- W4308608833 hasConcept C2777451236 @default.
- W4308608833 hasConcept C2780551157 @default.
- W4308608833 hasConcept C555293320 @default.
- W4308608833 hasConcept C57658597 @default.
- W4308608833 hasConcept C71924100 @default.
- W4308608833 hasConcept C98274493 @default.
- W4308608833 hasConceptScore W4308608833C126322002 @default.
- W4308608833 hasConceptScore W4308608833C134018914 @default.
- W4308608833 hasConceptScore W4308608833C141071460 @default.
- W4308608833 hasConceptScore W4308608833C197934379 @default.
- W4308608833 hasConceptScore W4308608833C2775887513 @default.
- W4308608833 hasConceptScore W4308608833C2777105317 @default.
- W4308608833 hasConceptScore W4308608833C2777180221 @default.
- W4308608833 hasConceptScore W4308608833C2777451236 @default.
- W4308608833 hasConceptScore W4308608833C2780551157 @default.
- W4308608833 hasConceptScore W4308608833C555293320 @default.
- W4308608833 hasConceptScore W4308608833C57658597 @default.
- W4308608833 hasConceptScore W4308608833C71924100 @default.
- W4308608833 hasConceptScore W4308608833C98274493 @default.
- W4308608833 hasLocation W43086088331 @default.
- W4308608833 hasOpenAccess W4308608833 @default.
- W4308608833 hasPrimaryLocation W43086088331 @default.
- W4308608833 hasRelatedWork W2492243411 @default.
- W4308608833 hasRelatedWork W2766009796 @default.
- W4308608833 hasRelatedWork W2928289028 @default.
- W4308608833 hasRelatedWork W3029803913 @default.
- W4308608833 hasRelatedWork W3041720083 @default.
- W4308608833 hasRelatedWork W4238299336 @default.
- W4308608833 hasRelatedWork W4295257021 @default.
- W4308608833 hasRelatedWork W4295259543 @default.
- W4308608833 hasRelatedWork W4308608833 @default.
- W4308608833 hasRelatedWork W4310255579 @default.
- W4308608833 isParatext "false" @default.
- W4308608833 isRetracted "false" @default.
- W4308608833 workType "article" @default.